These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 16397526)

  • 1. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
    Minucci S; Pelicci PG
    Nat Rev Cancer; 2006 Jan; 6(1):38-51. PubMed ID: 16397526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
    Botrugno OA; Santoro F; Minucci S
    Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors for epigenetic therapy of cancer.
    Monneret C
    Anticancer Drugs; 2007 Apr; 18(4):363-70. PubMed ID: 17351388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS; Parmigiani RB; Marks PA
    Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry in epigenetic research.
    Beck HC
    Methods Mol Biol; 2010; 593():263-82. PubMed ID: 19957154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: biology and mechanism of action.
    Mehnert JM; Kelly WK
    Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating zinc monkey wrenches in the treatment of epigenetic disorders.
    Kalin JH; Butler KV; Kozikowski AP
    Curr Opin Chem Biol; 2009 Jun; 13(3):263-71. PubMed ID: 19541531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC family: What are the cancer relevant targets?
    Witt O; Deubzer HE; Milde T; Oehme I
    Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
    Huang L
    J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDACi--targets beyond chromatin.
    Buchwald M; Krämer OH; Heinzel T
    Cancer Lett; 2009 Aug; 280(2):160-7. PubMed ID: 19342155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.